Galapagos NV 2023 AR2
The report highlights Galapagos' strategic transition into a pure-play biotechnology company in 2023, focusing on oncology and immunology. Key achievements include the successful transfer of the Jyseleca (filgotinib) business to Alfasigma and an integrated drug discovery collaboration with NovAliX. In oncology, the company advanced its decentralized CAR-T manufacturing platform, presenting encouraging Phase 1/2 data for GLPG5101 and GLPG5201. Financially, Galapagos reported a net profit of €211.7 million, driven by discontinued operations, and reduced its operational cash burn to €414.8 million. On sustainability, the company committed to becoming climate neutral by 2028, aligning with UN SDGs and completing a double materiality assessment.
Company: Galapagos NV
Sector: Health Care
Country: Belgium
Year: 2023
Type: AR2
Pages: 279
Galapagos NV
Annual Report
The report highlights Galapagos' strategic transition into a pure-play biotechnology company in 2023, focusing on oncology and immunology. Key achievements include the successful transfer of the Jyseleca (filgotinib) business to Alfasigma and an integrated drug discovery collaboration with NovAliX. In oncology, the company advanced its decentralized CAR-T manufacturing platform, presenting encouraging Phase 1/2 data for GLPG5101 and GLPG5201. Financially, Galapagos reported a net profit of €211.7 million, driven by discontinued operations, and reduced its operational cash burn to €414.8 million. On sustainability, the company committed to becoming climate neutral by 2028, aligning with UN SDGs and completing a double materiality assessment.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees